During an oral Spotlight Presentation, Codexis unveiled the successful end-to-end enzymatic synthesis of an entire approved siRNA therapeutic asset, inclisiran. Codexis enzymatically synthesized the ...
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at ...
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an ...
Diagram of the image of being able to distinguish differences in the state of nucleic acids inside LNPs by evaluating their physical properties using NMR. Small interfering RNA (siRNA) molecules hold ...
New findings point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer. In everyday life, when things turn out ...
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback